A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
A new report released Monday by UnitedHealth Group finds that administering specialty drugs—which are typically injected or infused—in homes or in independent physician offices instead of hospitals could save as much as $4 billion each year.
The report focused on the 5 conditions—multiple sclerosis (MS), immune deficiency, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and chemotherapy—that account for more than 75% of spending on administered drugs.
Changing the setting of administration would save $16,000 to $37,000 per privately insured patient per year, the report said, reflecting a savings opportunity between 33% and 52%.
By condition, the report separated monthly costs by place of administration:
For 2 conditions—RA and IBD—costs were slightly higher when drugs were administered at home versus a provider’s office, but both sites were still far less than hospital settings.
For chemotherapy, the report found a $16,000 savings for 4 months of treatment ($8281 monthly costs for a provider’s office and $12,315 for a hospital setting).
The report comes as the use of specialty drugs is increasing; since 2013, annual growth in per capita spending on administered specialty drugs has averaged 14%. With healthcare costs expected to reach $6 trillion by 2027, policymakers have been grappling with different ideas to try to reverse the trends.
The report said that treating patients at home could add to physical and mental wellbeing, with fewer schedule disruptions related to work or family, without the likelihood of adverse drug events or side effects.
Compared to independent physician offices, hospitals charge more for specialty drugs and their administration, whether treatment occurs in a hospital or in a hospital-owned physician practice.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.